1 Local resistance management and containment response Dr Wichai Satimai: Director, Bureau of Vector Borne Diseases, Department of Disease Control, Ministry.

Slides:



Advertisements
Similar presentations
Current Malaria Related Operational Research Activities in Ethiopia Amha Kebede Deputy Director, EHNRI.
Advertisements

WHO Regional Director for the Western Pacific Dr Shin Young-soo Malaria in the Pacific – Successes and Challenges.
22-24 November 2011 Community Engagement for Malaria Elimination Workshop Centara Duangtawan Hotel, Chiang Mai, Thailand.
Private Sector Malaria Case Management: Experience from 7 years of implementation in Cambodia Presented by Dr. Socheat, Director of CNM RBM Working Group.
National Strategic Plan for Elimination of Malaria in Cambodia ( )
Shunmay Yeung LSHTM Malaria Day talk April 29, 2010 The problem with drugs…. ……..is they don’t last forever.
Malaria Elimination in Zanzibar. Introduction Dramatic declines in malaria morbidity and mortality over the last decade (prevalence remained
Learning and Empowerment: “Key Issues in Strategies for HIV/AIDS Prevention” March 1-5, 2004, Chiang Mai Presented by Dr. Pum Sophiny, Program Officer.
APPMG World Malaria Day Event, 2013 Invest in The Future: Defeat Malaria Kolawole Maxwell, Malaria Consortium Nigeria Country Director.
Malaria in Zambia A refresher Scope of Presentation  Background on Malaria  Overview of malaria in Zambia  Interventions  Impact  Active Case.
Caroline Lynch & Jim Tulloch June 2014 Synthesis of current evidence on the multiple causes of malaria drug resistance.
Role of the laboratory in disease surveillance
Challenges & responses for malaria in Asia
Current Malaria Situation -Bangladesh MALARIA FACTS Country Area 147,570 sq. km and Pop million 13 out of 64 districts are high endemic 13.3 million.
Country report-Tanzania Presented to EARN Annual Malaria Conference Kigali, Rwanda 15th –19 th November, 2004 NMCP.
Regional initiative to sustain country achievement SEAR Krongthong Thimasarn Regional Adviser, Malaria World Health Organization Regional Office for South-
World Health Organization
Module 7: Malaria and HIV/AIDS Palliative Care for People Living with HIV/AIDS.
Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.
Combining Entomological, Epidemiological, and Space Mapping data for Malaria Risk-mapping in Northern Uganda Findings and Implications Ranjith de Alwis,
FUTURE RESEARCH ON MALARIA: Towards a malaria-free country Emiliana Tjitra National Institute of Health Research and Development Jakarta, 30 April 2015.
Malaria Landscape 2007 Executive Director's Report to the 13 th Board Meeting.
Malaria Situation & Drug Policy Malaysia Infectious Disease Consultant/Physician MOH Malaysia.
1 Eritrea National Malaria Control Program: On the road to malaria eradication Saleh Meky Minister of Health Government of Eritrea.
Zambia Active Parasite Detection Campaign 2011 Welcome!!
Post-MDA surveillance ( including xeno-monitoring) Krishnamoorthy K. Vector Control Research Centre Pondicherry India.
Roadmap Progress Report 2011 Zambia SARN-RBM PARTNERS ANNUAL CONSULTATIVE MEETING, JULY 2011.
Malaria Case management KPA conference. Presentation outline  Introduction  National malaria strategy  Case management targets  AMFm subsidy  The.
EPIDEMIOLOGY DENGUE, MALARIA Priority Areas for Planning Dengue Emergency Response 1. Establish a multisectoral dengue action committee.
Malaria treatment policies: the challenge, strategies and the options SOTA, Nairobi, Kenya 12 th June 2002.
1 Malaria Prevention and Control in Ethiopia Dr Daddi Jima National Malaria Control Program, Ethiopia.
Monitoring &Evaluation System in Health Program. Brief overview of NACP Reporting units and quality aspects Data sets Learning/ Analysis of the data sets.
Malaria--Background Occurs in > 90 countries million cases a year 2 million deaths a year –>90% deaths in sub-Saharan Africa –Most deaths in children.
Containment of artemisinin resistance at the Cambodia-Thailand border Sylvia Meek, Technical Director, Malaria Consortium, CMWG Meeting 8 July 2009.
Current National Drug Policies in Lao P.D.R. By Dr Samlane Phompida Centre of Malariology, Parasitology & Entomology.
Issues in malaria diagnosis and treatment May 31, 2007 Jacek Skarbinski, MD Malaria Branch Centers for Disease Control and Prevention.
Informal Consultation to Consolidate the Regional Response to Address Artemisinin Resistance and Substandard Antimalarial Medicines in the GMS, Bangkok,
Kanchanaburi, May 2007 A collaboration between: SMRU, MSF-F, AMI, IRC, ARC, MHD With the participation of TBBC and HIS/CCSDPT Malaria surveillance in camps.
1 Roadmap to Achieve RBM Targets Country January 2011 – December 2011 Botswana.
Strengthening SME system for national programmes moving from transmission reduction to elimination phase Cambodia.
Group B Comparison of the different types of programs.
Human resources for malaria elimination Deyer Gopinath GMS Malaria Elimination Course 10 – 21 August 2015, Chiang Mai, Thailand.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia & Dr. Michael Lynch Epidemiologist.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia.
Kenya Roadmap to Achieve RBM Targets September 2009 – December 2010.
Zambia Active Parasite Detection (APD) 2011 Questionnaire.
An update of artemisinin resistance and its containment efforts
Malaria elimination in the North Eastern Thailand
SOP for malaria case surveillance
CASE DETECTION by Dr Mikhail Ejov WHO Training in Malaria Elimination in the Greater Mekong Sub-Region, August 2015, Chiang Mai Thailand 1.
Swaziland Ministry of Health Swaziland’s Roadmap to Achieve RBM Targets January-December 2011.
AMI -RAVREDA – USAID Project report, Colombia March 2009 Preliminary results on efficacy and Safety of Coartem ® on the treatment of Acute Uncomplicated.
GMS Elimination Training Chiang Mai 14 th August 2015 Deyer Gopinath ENGAGING COMMUNITIES.
4 SELECTED PROVINCES FOR Elimination Preah Vihear Kratie Kep PAILIN.
Malaria Endemic Areas and Drug Resistance
Thailand TB Situation Dr. Chawetsan Namwat Director Bureau of Tuberculosis 23 August
Surveillance policies and practices in transmission-reduction and elimination phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS,
Unit 4 Approaches and Interventions in Pre- Elimination, Elimination and Prevention of Reintroduction Case Management, G6PD, etc and selections of interventions.
Bureau of Vector Borne Disease Control, Thailand. TES result in
2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.
Antimalarial Drugs.
World Health Organization
Malaria Elimination Programme Timor Leste
Human Resource Requirements for Malaria Elimination
Malaria in Tribal Areas
The analysis and advocacy (A2) project: Role in translating Thailand’s national AIDS strategy into provincial implementation plans S. Pantuwatana1, S.
Dr.Merita Monteiro Head of CDC Ministry of Health Timor Leste
Partners for Measles Advocacy 7th Annual Meeting
Dte. National Vector Borne Diseases Control Programme (NVBDCP), MOHFW
Len Tarivonda, Director of Public Health Ministry of Health
Presentation transcript:

1 Local resistance management and containment response Dr Wichai Satimai: Director, Bureau of Vector Borne Diseases, Department of Disease Control, Ministry of Public Health, Thailand 15 th RBM Partnership Board Meeting November 10-11, 2008 New Delhi, India

2 Goal To reduce malaria morbidity and mortality Objectives To prevent transmission of drug resistance Malaria To develop the network of all partners for malaria control

3 Myanmar Lao PDR Cambodia Malaysia N Source: Malaria Cluster, Department of Disease Control, MoPH Integrated Provinces Pre- integrated Provinces Vertical Program

4 Annual parasite incidence (per 1,000) and malaria mortality rate (per 100,000)

5

6 Fiscal Year Malaria Cluster, Department of Disease Control, Ministry of Public Health. Fiscal Year :Oct - Sep * Preliminary data Thai and Non-Thai malaria cases Fiscal Year

7 Fiscal Year Number of cases Source: Malaria Cluster, Department of Disease Control, Thai MoPH CQ ’45-‘73 SP ’73-’82 QT ’82-’85 MSP ’85-’90 M, MSP ’90-’95 M, M+ATS (2 days) ’95-’05 ’05-07 M+ATS 2 days; From ’08 3 days No. of Malaria Cases by Parasite Species and 1 st Line Drug Regimens for P. falciparum, Thailand,

8 Local resistance management

9 MYANMAR THAILAND LAOS VIETNAM MALAYSIA INDONESIA CAMBODIA GULF OF THAILAND ANDAMON SEA TUNGIA GULF 1.Chiang Mai 2. Mae Hong Son 3. Tak 4. Kanchanaburi 5. Ratchaburi 9. Trat 8. Chanthaburi 7. Ubonratchathani 6. Ranong Activities Routine follow- up In vivo testing In vitro testing Drug Quality Assurance Monitoring Malaria Drug Resistance in Thailand

10 Refs. Study site, YearDose Subjects (N) Follow-up durationEfficacy Mey Bouth et al, Siem Reap Conf., Pailin Cambodia 2002 AM4, AM3, AM2 3 days Children and adults (70) 28 days87.0% (PCR- corrected) Vijaykadga et al, TMIH Trat Thailand 2003 ATS (600 mg) + MFQ 1,250 mg) in 2 days Mostly adults (>=10 yrs) (44) 28 days78.6% Mey Bouth et al, TMIH Pailin Cambodia 2004 ATS 12 mg/kg in 3 days + MFQ 25 mg/kg. Children and adults (81) 42 days79.3% (PCR- corrected) Increasing Evidence of ATS-MFQ Failures on the Thai-Cambodian Border

11 Mef 25 mg/kg + Art 12 mg/kg + Pri 30 mg; two days regimen ** PCR corrected N ACPR% LPF% LCF% ETF% MHS 2006: 28d TAK 2006: 28d KB 2005: 28d RB 2006**: 42d RN 2004: 28d TR 2006: 28d Treatment Efficacy of Mefloquine and Artesunate against falciparum malaria at seven areas in Thailand,

12 D2 parasitemia is strongly associated with ATS-MFQ Rx failure (28-day FU): OR adj. = 4.15 (95%CI: , p 1,200). in vivo monitoring of ATS-MFQ therapeutic efficacy conducted by the Thai NMCP, Source: in vivo monitoring of ATS-MFQ therapeutic efficacy conducted by the Thai NMCP, (S Vijaykadga & AP Alker, ASTMH 2008 presentation). [ Since MFQ is more slow-acting, ATS is the major determinant of parasite clearance on D2/D3 in ATS-MFQ Rx, given D0 = day of Rx initiation. Presence of D2/D3 parasitemia indicates Delayed Parasite Clearance.] Sensitivity of P. falciparum to Artesunate?

13 Prevalence of parasitemia on D2 postRx has significantly increased over the past decade on Thai-Camb border, but not on Thai-Burmese border. Source: Thai MOPH Thai NMCP’s ATS-MFQ in vivo monitoring of 1,267 Pf patients OR(adj.)* for each year: - Cambodian border 1.40 (95% CI: 1.2, 1.7, p<0.0001)* - Burmese border 0.98 (95% CI: 0.8, 1.2, p=0.83) *The odds of D2 parasitemia increases, on average, 40% per year on the Cambodian border but not increasing on the Burmese border. Sensitivity of P. falciparum to Artesunate?

14 Tak Ran ong Kanchana buri Ratchabur i Trat Artesunate 12mg/kg + Mefloquine 25 mg/kg Divided dose given for 2 days Antimalarial efficacy in the treatment of falciparum malaria patients in the year 2007 Mae Hong Son

15

16 Constraints and key challenges Multi-drug resistant of falciparum malaria. High proportion of reported foreign malaria cases, thus scaling up the effective interventions in all endemic villages focusing on both Thai and Non- Thai population is essential. Increase of cases in the unrest areas along the southern border provinces, thus scaling up the effective interventions in this area is needed. The program is being decentralized resulting in decrease of specialized field staff, thus capacity building of local health personnel on malaria control is needed

17 Why multi-drug resistance was constraint to Malaria Control in Thailand? A large number of migrant laborers coming from different malarious areas import different strains/genotypes of P.falciparum and over a period of time mixed population of different strains/genotypes infect individuals. High population movement along the border still happened from both side, especially during harvesting and agriculture season. Unknown factors influence to multi drug resistance, more further research are needed.

18 Containment response Containment of artemisinin-tolerant P. falciparum parasites in 7 provinces in Thailand in 2009 – Phase 1: Containment of artemisinin-tolerant P. falciparum parasites in 7 provinces in Thailand in 2009 – Request fund from Bill- Milinda Gate Foundation Request fund from Bill- Milinda Gate Foundation Phase 2: Containment of artemisinin-tolerant P. falciparum parasites in 7 provinces in Thailand Request fund from GFM R9

19 Goal Containment of artemisinin-tolerant Plasmodium falciparum parasites in 7 provinces in Thailand in

20 Malaria cases in Thai-Cambodian Border, No cases

21 Zone 1 and 2 Containment Implementation Areas in Zone 1 and 2 Myanmar Lao PDR Cambodia Malaysia N Trat 2.Chanthaburi 3.Sakaeo 4.Burirum 5.Surin 6.Srisaket 7.Ubonratchathani

22 Chantaburi Containment Implementation Areas in Zone 1 (2008) Tamb onvillpop PongNamr on , 652 Soidao , 634 Borai , 871 Total , 157

23 Mass Screening Patients Vectorborne Disease Control Center VBDC Office of Disease Prevention and Control ODPC Vector Borne Disease Control Unit VBDU Ministry of Public Health MOPH Remote Areas BIOPHICS Mahidol University Malaria Center Health Volunteers equipped with loaded Malaria Application PDA GIS Mapping SMS Drug Resistance Alert / FU treatment monitoring Malaria Reports and Warning System Internet Drug Resistance Action Team

24 1.To eliminate artemisinin tolerant parasites by detecting all malaria cases in target areas and ensuring effective treatment and gametocyte clearance using zone specific combination therapies. Change the first line treatment for uncomplicated falciparum malaria in Zone 1 to a non artemisinin containing combination Improve coverage of passive case detection: MC and MP Conduct active case detection: mass screening of migrants and focus investigation. Implement directly observed treatment and conduct 28 day follow up of all confirmed falciparum malaria cases. Establish management system for treatment failure cases Objectives and activities

25 Objectives and activities 2.To prevent transmission of artemisinin tolerant parasites by mosquito control and personal protection.  Increase coverage of LLINs to 1 per person (residents, migrants and military)  Distribute LLI hammock nets for personal protection for local residents, migrants and military spending nights in the forest  Distribute repellents for personal protection for plantation workers and soldiers patroling at night.  Conduct IRS in foci of transmission detected as a result of case investigation.

26 Objectives and activities 3.To support containment/elimination of artemisinin tolerant parasites through comprehensive BCC, community mobilisation and advocacy  Review communication/BCC strategy and develop strategy for containment (harmonized with that of Cambodia) targeting all risk groups.  Implement BCC/IEC, including massive health promotion & community mobilization to ensure high turnout for ITN campaign and to promote appropriate use.

27 Objectives and activities 4.To undertake basic and operational research to fill knowledge gaps and ensure that strategies are evidence-based  Characterization of artemisinin tolerant parasites through: clinical trials (including PK studies); development of an in vitro test and molecular markers  Mapping of artemisinin tolerant parasites in 8 sentinel sites using a simplified in vivo test and molecular markers; assessment of effectiveness of Malaria Posts.  Monitoring residual effect of LLIN/LLIHN in sentinel sites; acceptability of all net types; entomological study in areas of changing forest ecology; assess additional protection of using repellents.  Studies to characterize mobile/migrants population movement and behavior; Assessment of feasibility and impact of mass screening and treatment to eliminate artemisinin  Assess the effectiveness of mass screening and treatment of positive cases to detect and treat asymptomatic Pf. infections

28 5.Provide effective management system to enable rapid and high quality implementation of the strategy  Establish and maintain comprehensive malaria surveillance and active case investigation system in 13 Provinces bordering with Cambodia and Myanmar.  Hold cross-border coordination meetings.  Establish migrant networks to improve information sharing on malaria in source, transit and destination communities and at work sites  Strengthen human resources at all levels for management and implementation related to containment efforts  Increase supervision capacity to cope with containment associated increase in workload.  Strengthen collection of routine M&E data. Objectives and activities

29 ขอบคุณ